Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital
|
|
- Laurel Reeves
- 6 years ago
- Views:
Transcription
1 Journal of Infection and Public Health (2013) 6, Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital M.A. De Francesco, G. Ravizzola, L. Peroni, C. Bonfanti, N. Manca 1 Institute of Microbiology, University of Brescia, Italy Received 3 August 2012; received in revised form 30 November 2012; accepted 30 November 2012 KEYWORDS P. aeruginosa; A. baumannii; Antibiotic resistance; Infection; Antibiotics Summary The severity and extent of disease caused by multidrug-resistant organisms (MDROs) varies by the population(s) affected and the institution(s) at which these organisms are found; therefore, preventing and controlling MDROs are extremely important. A retrospective study of patients who were infected with Acinetobacter baumannii or Pseudomonas aeruginosa was performed at the Spedali Civili Hospital in Brescia, Italy, from 2007 to A total of 167 (0.52%) A. baumannii isolates and 2797 P. aeruginosa (8.7%) isolates were identified among 31,850 isolates. Amikacin and colistin were the most active agents against A. baumannii strains. Multidrug resistance (MDR) was observed in 57 isolates (54%). Most MDR isolates (42 out of 57, 73%) were resistant to four classes of antibiotics. P. aeruginosa was recovered more frequently from the respiratory tract, followed by the skin/soft tissue, urine and blood. Colistin, amikacin and piperacillin/tazobactam were active against 100%, 86% and 75% of P. aeruginosa isolates, respectively. A total of 20% (n = 316) of P. aeruginosa isolates were MDR. In summary, A. baumannii was more rare than P. aeruginosa but was more commonly MDR. Epidemiological data will help to implement better infection control strategies, and developing a local antibiogram database will improve the knowledge of antimicrobial resistance patterns in our region King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved. Corresponding author at: Institute of Microbiology, P. le Spedali Civili, 1, Brescia, Italy. Tel.: ; fax: address: defrance@med.unibs.it (M.A. De Francesco). 1 The paper is dedicated to the memory of the late Professor Nino Manca /$ see front matter 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.
2 180 M.A. De Francesco et al. Introduction Nosocomial infections are one of the most common complications of hospitalization and lead to increased morbidity and mortality [1,2]. These infections prolong hospitalization, require more extensive diagnostics and treatment and are associated with additional costs [3,4]. Infection with multidrug-resistant pathogens can also complicate treatment. Antibiotic resistance is a daunting phenomenon with a growing impact on patient safety, particularly in ICUs [5]. Critically ill patients are prone to colonization and infection by antibiotic-resistant bacteria because of the frequent exposure of these patients to antibiotics and the presence of multiple, often invasive, devices. This dangerous array of risk factors drives a vicious cycle of increased infection incidence, increased need for broadspectrum antibiotics, reduced antimicrobial efficacy and increased selection of antibiotic resistance. Multidrug-resistant organisms (MDROs) are resistant to one or more classes of antimicrobial agents, such as -lactams (penicillins, cephalosporins, monobactams and carbapenems), fluoroquinolones and aminoglycosides. During the past several decades, a shift in the MDR dilemma from gram-positive to gram-negative bacteria has been noted, which is in part due to the small number of new antimicrobial agents that are active against resistant gram-negative strains [6]. Gramnegative pathogens that have acquired epidemiological importance among nosocomial infections include Acinetobacter baumannii and Pseudomonas aeruginosa. A. baumannii is a cause of outbreaks in hospitals [7,8], and the MDR patterns observed among isolates often leave carbapenems as the only effective treatment for severe infections [8]. However, carbapenem-resistant A. baumannii is emerging worldwide and has been observed in different countries [7,9 11]. There are limited therapeutic options for infections caused by these isolates. P. aeruginosa is also a common gram-negative nosocomial pathogen. This organism is an important cause of hospital-acquired pneumonia and urinary tract, wound and bloodstream infections [12]. Infections caused by this pathogen are often difficult to treat because of the multidrug-resistant nature of this bacterial species, and P. aeruginosa strains are often carbapenem resistant, which can severely limit the available therapeutic choices [13]. The purposes of this study were the following: (a) to determine the prevalences of A. baumannii and P. aeruginosa in patients with nosocomial infections at Brescia s main hospital; and (b) to analyze the antimicrobial susceptibility patterns of these two microorganisms determined as part of an internal laboratory surveillance study from 2007 to Methods Bacterial isolates A retrospective study of all A. baumannii and P. aeruginosa isolates from different clinical specimens collected from patients with nosocomial infections and processed by the microbiology laboratory between 2007 and 2010 was conducted at the Spedali Civili Hospital in Brescia, Italy. Spedali Civili is a major hospital with an average of approximately 47,000 hospitalizations annually. Infections were considered nosocomial if they first appeared 48 h after admission. Infections that were likely to have been acquired before hospital admission were not considered nosocomial. Blood, urine, tracheal aspirate, bronchi alveolar lavage, sputum, purulent wound, skin ulcer and catheter tip samples collected from patients admitted to all units (ICU and other departments) were eligible. Duplicate isolates were excluded. Clinical specimens were plated onto blood agar and MacConkey agar and incubated overnight at 37 C. After incubation for 24 h at 37 C, the organisms were identified using the VitekTM system (biomerieux, Marcy-l Etoile, France). Antimicrobial susceptibility Antimicrobial susceptibility was assessed using the Vitek2 system (biomerieux) and the AST-GN24 card according to the manufacturer s instructions. The results obtained after a maximum of 15 h of incubation were analyzed and interpreted by AES 4.02 software. The MICs determined by the system identified the microorganism as susceptible, intermediate or resistant according to the criteria published by the CLSI [14]. Antibiotic resistance was categorized into five groups: (1) resistance to extended-spectrum penicillins (piperacillin/tazobactam), (2) resistance to cephalosporins (ceftazidime), (3) resistance to carbapenems (imipenem), (4) resistance to aminoglycosides (amikacin) and (5) resistance to quinolones (ciprofloxacin). The breakpoints for these antimicrobials were as follows: amikacin, S 16 and R 32; ceftazidime, S 8 and R 16; imipenem,
3 Multidrug-resistant A. baumannii and P. aeruginosa 181 Table 1 Prevalence of A. baumannii strains obtained during the study period and their distributions in different clinical samples. A. baumannii Total = 23 a Total = 21 Total = 48 Total = 75 No. of infections/colonizations b A. baumannii No (%) No (%) No (%) No (%) Type of infected/colonized specimen Respiratory tract 8 (38) 6 (35.3) 18 (50) 24 (52.2) Skin/soft tissue 7 (33.3) 7 (41.2) 10 (27.8) 15 (32.6) Blood 1 (4.8) 3 (17.6) 4 (11.1) 0 Urine 3 (14.3) 0 2 (5.5) 3 (6.5) Other clinical specimens 2 (9.6) 1 (5.9) 2 (5.5) 4 (8.7) a Total strains, including duplicates. b All clinical specimens positive for A. baumannii;. S 4 and R 16; ciprofloxacin, S 1 and R 4 (all for both strains); and piperacillin/tazobactam, S 16/4 and R 64/4 for A. baumannii strains and S 64/4 and R 128/4 for P. aeruginosa strains. Colistin susceptibility was tested using the Kirby Bauer disk diffusion with 10 g colistin disks (OXOID S.p.A., Milan, Italy). The inhibition zone diameters were interpreted according to the CLSI guidelines for colistin (resistant 10 mm and susceptible 11 mm). The strains were defined as R0 (absence of resistance to all five classes of antibiotics), R1 (resistant to one class of antibiotics), R2 (resistant to two classes of antibiotics), R3 (resistant to three classes of antibiotics), R4 (resistant to four classes of antibiotics) and R5 (resistant to five classes of antibiotics). In agreement with previous reports, the term multidrug resistance was used to describe resistance to three or more classes of antimicrobial agents [15,16]. Statistical analysis The Fisher exact test and the chi-square test for linear trend analysis were used to evaluate both the differences in the distributions of the isolates and the trend in the susceptibility rate. A p value of <0.05 was considered significant. Results A. baumannii Among the 31,850 isolates collected from hospitalized patients over the 4-year study period, 167 (0.52%) were identified as A. baumannii. Specimens were collected from the respiratory tract (46.6%; n = 56), skin/soft tissue (32.5%; n = 39), blood (6.6%; n = 8), urine (6.6%; n = 8) and other locations (7.5%; n =9) (Table 1). Increases in the percentages of strains isolated from the respiratory tract and skin/soft tissue were observed in 2009 and More A. baumannii isolates than P. aeruginosa isolates were resistant to the tested antibiotics (Table 2). The percentage of susceptible A. baumannii strains was 82% for amikacin, approximately 20% for imipenem and piperacillin/tazobactam and 16% for ceftazidime and ciprofloxacin. All strains were susceptible to colistin. Fifty-seven isolates (54%) were MDR (Table 3). Three isolates were resistant to three classes of antibiotics, and most MDR isolates (42 out of 57, 73%) were resistant to four classes of antibiotics. Eleven isolates were resistant to all five classes of antimicrobials. A significant increase (p < 0.05) in the percentage of R5 isolates was observed in P. aeruginosa P. aeruginosa was identified in 2797 isolates (8.8%) of the 31,850 isolates collected from hospitalized patients during the study period. Like A. baumannii, most P. aeruginosa strains were recovered from the respiratory tract (42.8%; n = 790), followed by skin/soft tissue (26%; n = 480), urine (13.5%; n = 349), other clinical specimens (11%; n = 204) and blood cultures (6.5%; n = 121) (Table 4). However, a significant decrease (p < 0.01) in the percentage of P. aeruginosa strains isolated from the respiratory tract over time was observed;
4 182 M.A. De Francesco et al. Table 2 Antimicrobial susceptibility patterns of 167 A. baumannii and 2797 P. aeruginosa strains collected from 2007 to Antimicrobial agents A. baumannii P. aeruginosa CLSI breakpoint interpretation CLSI breakpoint interpretation %S %I %R %S %I %R Amikacin Ceftazidime Ciprofloxacin Imipenem Piperacillin/tazobactam %S = percent susceptible; %I = percent intermediate; %R = percent resistant. Table 3 Trends in the antimicrobial resistance patterns of A. baumannii isolates tested from 2007 to n =21 n =17 n =31 n =36 R0 11 (52.4) 8 (47) 11 (35.5) 10 (27.8) R1 1 (4.8) 2 (11.8) 1 (3.2) 1 (2.8) R2 0 1 (5.9) 1 (3.2) 1 (2.8) R3 a (6.5) 1 (2.8) R4 a 9 (42.8) 5 (29.4) 15 (48.4) 14 (38.8) R5 a 0 1 (5.9) 1 (3.2) 9 (25) * a Multidrug-resistant isolates. * p < ** p < Table 4 Prevalence of P. aeruginosa strains obtained during the study period and their distribution in different clinical samples. P. aeruginosa Total = 575 a Total = 732 Total = 798 Total = 692 b No. of infections/colonizations P. aeruginosa No (%) No (%) No (%) No (%) Type of infected/colonized specimen Respiratory tract 198 (54.7) 197 (41) ** 216 (40) ** 179 (38) ** Skin/soft tissue 79 (21.8) 154 (32) ** 133 (25) 114 (24.5) Blood 14 (3.9) 32 (6.6) 44 (8.2) ** 31 (6.6) Urine 65 (18) 52 (11) ** 71 (13.3) 61 (13.1) Other clinical specimens 6 (1.6) 47(9.7) ** 70 (13) ** 81 (17) ** a Total strains, including duplicates. b All clinical specimens positive for P. aeruginosa. * p < ** p < 0.01.
5 Multidrug-resistant A. baumannii and P. aeruginosa 183 Table Trends in the antimicrobial resistance patterns of Pseudomonas aeruginosa isolates tested from 2007 to n = 328 n = 402 n = 452 n = 392 R0 141 (43) 179 (44.5) 214 (47.3) 163 (41.6) R1 63 (19.2) 87 (21.7) 82 (18.1) 89 (22.7) R2 60 (18.3) 62 (15.4) 69 (15.3) 49 (12.5) R3 a 31 (9.5) 29 (7.2) 23 (5.1) * 42 (10.7) ** R4 a 26 (7.9) 37 (9.2) 49 (10.8) 33 (8.4) R5 a 7 (2.1) 8 (2) 15 (3.4) 16 (4.1) a Multidrug-resistant isolates. * p < ** p < in contrast, a significant increase was observed in the recovery of P. aeruginosa from different clinical specimens (p < 0.01). Colistin (100% susceptible), amikacin (85%) and piperacillin/tazobactam (75%) had the highest susceptibility rates among the antimicrobial agents tested. The susceptibility rates for carbapenems and cephalosporins ranged from 64% for imipenem to 69% for ceftazidime. Lower activity was observed for ciprofloxacin (58%). Of the 1574 isolates from infected/colonized patients, 20% (n = 316) were MDR (Table 5). Most isolates were resistant to four classes of antibiotics (145 out of 316, 45.8%), followed by three classes of antibiotics (125 out of 316, 39.5%) and all five classes of antimicrobial agents (46 out of 316, 14.5%). A significant decrease (p < 0.05) in the percentage of R3 strains was observed from 2007 to 2009, followed by a significant increase (p < 0.01) from 2009 to Discussion The data collected as part of an internal laboratory surveillance program were used in the present study to draw conclusions about the occurrence of epidemiologically important pathogens responsible for nosocomial infections. Despite the increased rates of A. baumannii infection reported worldwide and the findings of the clonal expansion of these microorganisms in clinical settings, particularly ICUs [7,8,17], A. baumannii represented only 0.52% of all organisms isolated over the 4-year study period. The most serious current problem regarding the treatment of Acinetobacter infections is acquired MDR, resulting in the availability of few effective antimicrobial agents. MDR can be to the result of the presence of a single resistance determinant that confers resistance to more than one class of antimicrobial agent, such as MDR pumps. MDR can also be due to the presence of multiple resistance determinants [18]. Some strains of A. baumannii that are resistant to all antibiotics have been detected [19,20]. A surveillance study in Korea in 2009 [21] showed that the resistance rates of Acinetobacter were very high: 67% of isolates were resistant to fluoroquinolones, 48% to amikacin, 66% to ceftazidime and 51% to imipenem. This resistance trend was largely similar to that observed in a study conducted by The Surveillance Network (TSN) in the U.S. [22]. In our study, we observed more frequent resistance to imipenem (80%), ceftazidime and ciprofloxacin (84%), whereas resistance to amikacin was less frequent (18%). Fifty-seven isolates (54%) were MDR, with an increase in the percentage of strains resistant to all five classes of antibiotics. Nosocomial strains of P. aeruginosa are frequently resistant to a broad range of antibiotics. The prevalence of nosocomial strains of P. aeruginosa appears to be increasing worldwide, especially as a cause of ventilator-associated pneumonia; their prevalence in high-risk populations, such as patients with severe burn injuries, is also increasing [23]. Pseudomonas is most commonly isolated from the respiratory tract, followed by wounds, urine and blood [19]. This finding is in agreement with our results. Pseudomonas is intrinsically resistant to most antibiotics. Antimicrobial resistance develops under selective pressure, and multiple mechanisms are responsible: the (hyper-) production of enzymes, such as beta-lactamases and DNA gyrases; active efflux pumps; and permeability changes [19]. Our results show that colistin, amikacin and piperacillin/tazobactam were the most active antipseudomonal antimicrobials evaluated, a result
6 184 M.A. De Francesco et al. that is corroborated by the findings of other studies [12]. Additionally, the limited activity of ciprofloxacin could be due to the overuse of this antimicrobial agent in clinical settings. In this study, we found that 316 strains (20%) were MDR. The majority of isolates were resistant to four classes of antibiotics (145 out of 316, 45.8%). Among MDR P. aeruginosa isolates, colistin showed good activity and could therefore be a useful alternative treatment; however, this agent is has considerable toxicity [15,24]. The ongoing surveillance of these microorganisms is important to help direct antimicrobial therapy and monitor the emergence of potentially drug-resistant strains in Brescia, Italy. Conflict of interest None declared. Funding No funding sources. Ethical approval Not required. References [1] Geffers C, Sohr D, Gastmeier P. Mortality attributable to hospital-acquired infections among surgical patients. Infection Control and Hospital Epidemiology 2008;229: [2] Aranaz-Andres JM, Albar- Remon C, Vitaller-Murillo J, Ruiz- Lòpez P, Limon-Ramìrez R, Terol-Garcia E, et al. Incidence of adverse events related to health care in Spain: results of the Spanish National Study of Adverse Events. Journal of Epidemiology and Community Health 2008;62: [3] Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271: [4] Beyersmann J, Gastmeier P, Grundmann H, Bärwolff S, Geffers C, Behnke M, et al. Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection. Infection Control and Hospital Epidemiology 2006;27: [5] Bonten MJ. Healthcare epidemiology: ventilator-associated pneumonia-preventing the inevitable. Clinical Infectious Diseases 2011;52: [6] Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 2009;48:1 12. [7] Morgan DJ, Weisenberg SA, Augenbraun MH, Calfee DP, Currie BP, Furuya EY, et al. Multi-drug resistant Acinetobacter baumannii in New York City 10 years into the epidemic. Infection Control and Hospital Epidemiology 2009;30: [8] Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti K, Maniatis AN, et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. Journal of Antimicrobial Chemotherapy 2006;57: [9] Livermore DM, Hill RL, Thomson H, Charlett A, Turton JF, Pike R, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem and multiply-resistant Acinetobacter baumannii around London. International Journal of Antimicrobial Agents 2010;35: [10] Peleg A, Seifert H, Paterson DL. Acinetobacter baumannnii: emergence of a successful pathogen. Clinical Microbiology Reviews 2008;21: [11] Ying CM, Ling TK, Lee CC, Ling JM. Characterization of carbapenem-sensitive and-resistant Acinetobacter baumannii in Shangai and Hong Kong. Journal of Medical Microbiology 2006;55: [12] Walkty A, Decorby M, Nichol K, Mulvey MR, Hoban D, Zhanel G, et al. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian National Intensive Care Unit study. Diagnostic Microbiology and Infectious Disease 2008;61: [13] Scheffer MC, Bazzo ML, Steindel M, Darini AL, Climaco E, Dalla-Costa LM. Intrahospital spread of carbapenemresistant Pseudomonas aeruginosa in a University Hospital in Florianopolis, Santa Catarina, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2010;43: [14] Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing. M100-S20 M-2 and M-7, Wayne, PA; [15] Falagas ME, Kasiakou SK. Colistin: the re-emerging antibiotic for multi-drug resistant Gram-negative bacterial infections. Clinical Infectious Diseases 2005;40: [16] McCracken M, DeCorby M, Fuller J, Loo V, Hoban DJ, Zhanel GG, et al. Identification of multi-drug and carbapenemresistant Acinetobacter baumannii in Canada: results from the CANWARD Journal of Antimicrobial Chemotherapy 2009;64: [17] Chaster J. Infections due to Acinetobacter baumannii in the ICU. Seminars in Respiratory and Critical Care Medicine 2003;24: [18] Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. New England Journal of Medicine 2010;362: [19] Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Current Opinion in Critical Care 2003;9: [20] Mahgoub S, Ahmed J, Glatt AE. Completely resistant Acinetobacter baumannii strains. Infection Control and Hospital Epidemiology 2002;23: [21] Lee K, Lee MA, Lee CH, Lee J, Roh KH, Kim S, et al. Increase of ceftazidime and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and Yonsei Medical Journal 2010;51: [22] Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii : increase of carbapenem-associated multiclass resistance in the United States. Microbial Drug Resistance 2010;16:
7 Multidrug-resistant A. baumannii and P. aeruginosa 185 [23] Brusselaers, Monstrey S, Snoeij T, Vandijck D, Lizy C, Hoste E, et al. Morbidity and mortality of bloodstream infections in patients with severe burn injury. American Journal of Critical Care 2010;19:81 7. [24] Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. International Journal of Antimicrobial Agents 2005;26: Available online at
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationPrevalenceofAntimicrobialResistanceamongGramNegativeIsolatesinanAdultIntensiveCareUnitataTertiaryCareCenterinSaudiArabia
: K Interdisciplinary Volume 17 Issue 4 Version 1.0 Year 2017 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN:
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationMulti-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes
Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationAcinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia.
Biomedical Research 12; 23 (4): 571-575 ISSN 97-938X Scientific Publishers of India Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia. Nazmul MHM, Jamal
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Antibiotic Susceptibility Pattern of Pseudomonas Aeruginosa Isolated From Various Clinical
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationLearning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationInternational Journal of Pharma and Bio Sciences ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI ABSTRACT
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI * PRABHAKAR C MAILAPUR, DEEPA
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationProtocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland
Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationCarbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S
Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***
More informationAntimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali,
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/88030.htm Antimicrobial Susceptibility Patterns of Salmonella Typhi From Kigali, Rwanda. Ashok
More informationGeorgios Meletis, Efstathios Oustas, Christina Botziori, Eleni Kakasi, Asimoula Koteli
New Microbiologica, 38, 417-421, 2015 Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationInfection Prevention and Control Policy
Infection Prevention and Control Policy Control of Multi-Drug-Resistant Gram-Negative Bacilli N.B. Staff should be discouraged from printing this document. This is to avoid the risk of out of date printed
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationPrevalence and Resistance pattern of Pseudomonas strains isolated from ICU Patients
ISSN: 2319-7706 Volume 3 Number 3 (2014) pp. 527-534 http://www.ijcmas.com Original Research Article Prevalence and Resistance pattern of Pseudomonas strains isolated from ICU Patients T.Raakhee 1 * and
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationMDRO in LTCF: Forming Networks to Control the Problem
MDRO in LTCF: Forming Networks to Control the Problem Suzanne F. Bradley, M.D. Professor of Internal Medicine Division of Infectious Disease University of Michigan Medical School VA Ann Arbor Healthcare
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationOvernight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
TABLE 1. Origin and carbapenem resistance characteristics of the 64 Acinetobacter baumannii stock D-750 Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationAcinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof.
Acinetobacter Resistance in Turkish Tertiary Care Hospitals Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Problem Countries that have reported hospital outbreaks of carbapenem-resistant Acinetobacter
More informationAntimicrobial stewardship in companion animals: Welcome to a whole new era
Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationORIGINAL ARTICLE /j x. Mallorca, Spain
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01251.x Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit
More informationReport on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
More informationSamantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationHospital ID: 831. Bourguiba Hospital. Tertiary hospital
Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017
More informationDr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center,
Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Hospital Authority NDM-1, which stands for New Delhi Metallo-beta-lactamase-1
More informationReceived 10 November 2006/Returned for modification 9 January 2007/Accepted 17 July 2007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2007, p. 3726 3730 Vol. 51, No. 10 0066-4804/07/$08.00 0 doi:10.1128/aac.01406-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationIsolation of Urinary Tract Pathogens and Study of their Drug Susceptibility Patterns
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 4 (2016) pp. 897-903 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.504.101
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL
ALARMING RATES OF PREVALENCE OF ESBL PRODUCING E. COLI IN URINARY TRACT INFECTION CASES IN A TERTIARY CARE NEUROSPECIALITY HOSPITAL Pearl. A Prabal*,Sourav Maiti Institute of Neurosciences, Kolkata, India
More informationCarbapenemase-Producing Enterobacteriaceae (CPE)
Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationThe First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran
1 2 The First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran Sedigheh Rafiei Tabatabaei, MD, MPH Associate Professor of Pediatric Infectious Diseases
More informationcrossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-negative pathogens between
RESEARCH ARTICLE Clinical Science and Epidemiology crossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline
More informationMultidrug-Resistant Gram-Negative Bacterial and Carbapenem-Resistant Enterobacteriaceae Infections in the Department of the Navy: Annual Report 2013
Multidrug-Resistant Gram-Negative Bacterial and Carbapenem-Resistant Enterobacteriaceae Infections in the Department of the Navy: Annual Report 2013 NMCPHC-EDC-TR-139-2015 By Paul Meddaugh and Uzo Chukwuma
More informationThe Nuts and Bolts of Antibiograms in Long-Term Care Facilities
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
More information